Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by M. Guillaume.
Respiration | 2006
Karim Zouaoui Boudjeltia; Alain Van Meerhaeghe; Sonia Doumit; M. Guillaume; Philippe Cauchie; Dany Brohée; Michel Vanhaeverbeek; Myriam Kerkhofs
Background: Recent reports have identified the apnoea and hypopnoea index (AHI) as an additional independent risk factor for cardiovascular morbidity and mortality. However, several studies reported contradictory results about the association between the serum C-reactive protein (CRP) level and the severity of apnoea. Objective: The purpose of this work is to study this association in patients referred to the sleep laboratory for clinical suspicion of sleep apnoea and presenting a wide range of AHI. Methods: Forty-nine consecutive patients were included in the study. The SigmaStat® software package (Jandle Scientific) was used. Multilinear regression analysis was tested using a stepwise backward selection of the explicative variables. The clinical characteristics (diabetes, hypertension, smoking habits, gender) were treated as dichotomous variables, while all other data (age, BMI, lipids, white blood cells) were continuous ones; high-sensitivity (hs)-CRP was the dependent variable. Results: In univariate analysis, AHI was correlated to hs-CRP: R = 0.43, p = 0.002. In multivariate analyses, we found an independent association between the AHI, adjusted for classical cardiovascular risk factors, and hs-CRP. Conclusion: In a sample of 49 patients, referred to the sleep laboratory for suspicion of sleep apnoea in routine practice, we observed an independent association between the AHI and hs-CRP.
BMC Biotechnology | 2002
K. Zouaoui Boudjeltia; Ph. Cauchie; Cl. Remacle; M. Guillaume; D. Brohee; Jl Hubert; M. Vanhaeverbeek
BackgroundDetermination of clot lysis times on whole blood, diluted whole blood, plasma or plasma fraction has been used for many years to assess the overall activity of the fibrinolytic system. We designed a completely computerised semi-automatic 8-channel device for measurement and determination of fibrin clot lysis. The lysis time is evaluated by a mathematical analysis of the lysis curve and the results are expressed in minute (range: 5 to 9999). We have used this new device for Euglobulin Clot Lysis Time (ECLT) determination, which is the most common test used in laboratories to estimate plasma fibrinolytic capacity.ResultsThe correlation between ECLT and manual method is very tight : R = 0,99; p < 10-6. The efficiency scores of the method are <4% in intra-assay and <7% in inter-assay. It allows to achieve the tests on hyperlipaemic samples. This new device has been easily integrated in laboratory routine and allows to achieve several ECLT every day without disturbance of laboratory workflow.ConclusionsThe routine use of this new device could be useful in various situations such as assessment in atherosclerosis and arteriosclerosis associated diseases, coagulation survey of liver transplantations, cardiovascular surgery or pharmacological research.It has already provided highly promising results in preliminary studies on the relation between fibrinolysis and cardiovascular risk factors.
Thrombosis Journal | 2004
Karim Zouaoui Boudjeltia; Michaël Piagnerelli; Dany Brohée; M. Guillaume; Philippe Cauchie; Jean Louis Vincent; Claude Remacle; Yves Bouckaert; Michel Vanhaeverbeek
Background-Endothelial cell dysfunction may be implicated in the development of multiple organ failure (MOF) by a number of mechanisms. Among these, altered fibrinolysis promotes fibrin deposition, which may create microvascular alterations during inflammation. Elevated concentrations of C-reactive protein (CRP), especially when these persist over time, are correlated with an increased risk of MOF and death. CRP may inhibit fibrinolysis by inducing plasminogen activator inhibitor-1 (PAI-1) release from human aortic endothelial cells. Moreover, the administration of recombinant CRP in volunteers may increase circulating PAI-1 levels.In this study, we tested the hypothesis that CRP is associated with hypofibrinolysis in intensive care patients with and without sepsis.Methods-We studied the association of inflammation and abnormal fibrinolysis in intensive care unit (ICU) patients with (n = 11) and without (n = 21) sepsis. The inflammatory response was assessed by serum concentration of C-reactive protein (CRP), a marker of the acute phase reaction, which increase rapidly in the inflammatory response, and the plasma fibrinolytic capacity was evaluated by the Euglobulin Clot Lysis Time (ECLT), determined by a new semi-automatic method.Results-ECLT was significantly higher in septic than non-septic patients (1104 ± 439 vs 665 ± 275 min; p = 0.002) and was significantly correlated with CRP concentration (R2 = 0.45; p < 0.001). In a multivariate analysis, CRP was the strongest predictor of ECLT (R2 = 0.51, F = 25.6, p < 0.001). In addition, the overall ICU length of stay was significantly correlated with CRP (R2 = 0.264, p = 0.003) and ECLT (R2 = 0.259, p = 0.003).Conclusion-In critically ill patients a significant correlation thus exists between plasma fibrinolytic capacity and serum CRP levels. Our data were obtained in the first 24 hours of ICU admission or of sepsis, thus, the relation between CRP and hypofibrinolysis appeared very quickly. This finding is compatible with a link between inflammation and abnormal fibrinolysis, and may explain the negative prognostic value of CRP in critically ill patients.
Biochemical and Biophysical Research Communications | 2004
K. Zouaoui Boudjeltia; N. Moguilevsky; Ilham Legssyer; Sajida Babar; M. Guillaume; Paul Delrée; M. Vanhaeverbeek; D. Brohee; J. Ducobu; ClaudeRemacleC. Remacle
Clinical Cardiology | 2006
C. Gillard; C. Henuzet; J. Lallemande; A. Moscariello; M. Guillaume; A. Van Meerhaeghe
Maturitas | 2006
K. Zouaoui Boudjeltia; C. Gregoir; M. Guillaume; Claude Remacle; Pietrina Piro; C. Garbar; J. Ducobu; Nicole Moguilevsky; M. Vanhaeverbeek; Paul Delrée; D. Brohee
Atherosclerosis Supplements | 2001
K. Zouaoui Boudjeltia; M. Guillaume; F. Kinard; Ph. Cauchie; ClaudeRemacleC. Remacle; J. Ducobu; M. Vanhaeverbeek; D. Brohee
Atherosclerosis | 1999
K. Zouaoui Boudjeltia; M. Guillaume; M. Vanhaeverbeek; E. Schonne; Ph. Cauchie; Cl. Remacle
Atherosclerosis Supplements | 2006
K. Zouaoui Boudjeltia; Patricia Stenuit; Maria José Esposito; M. Guillaume; D. Brohee; Ph. Cauchie; M. Vanhaeverbeek; Myriam Kerkhofs
Atherosclerosis Supplements | 2005
K. Zouaoui Boudjeltia; Ilham Legssyer; P. Van Antwerpen; S. Babar; M. Guillaume; Nicole Moguilevsky; M. Vanhaeverbeek; J. Ducobu; D. Brohee